Sobi appoints Mats-Olof Wallin as permanent Chief Financial Officer

Mats-Olof Wallin, who recently took on the role as interim Chief Financial
Officer (CFO), has been appointed Senior Vice President and CFO at Swedish
Orphan Biovitrum AB (publ.) (Sobi).
After a thorough search process supported by a senior Executive Search firm,
Mats-Olof Wallin was selected as the preferred candidate. Wallin brings more
than 30 years of experience in the pharmaceutical industry, gained from various
executive positions within companies such as Pharmacia, Ortivus and, most
recently, Biotage AB (publ.) where he held the role of CFO between 2003 and
2011. Wallin has been working at Sobi for the past several months.

"We are very pleased with the appointment of Mats-Olof as our permanent CFO.  We
have conducted a thorough search process and Mats-Olof has emerged as the most
suitable candidate for the job. He brings significant experience to the role and
has already proven to be a great addition to our senior team", said CEO Geoffrey


About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at

 For more information - not for

 Media relations                        Investor relations

 Oskar Bosson, Head of Communications   Jörgen Winroth, Vice President, Head of
                                        Investor Relations

 T: +46 70 410 71 80                    T: +46 8 697 20 00        


Documents & Links